SOURCE: Ablynx

August 19, 2010 12:12 ET

ABLYNX WILL ANNOUNCE HALF YEAR RESULTS FOR 2010 WITH WEBCAST

GHENT, BELGIUM--(Marketwire - August 19, 2010) - Ablynx [Euronext Brussels: ABLX] plans to announce its half year results for 2010 on 25 August 2010 after market closure.

Dr Edwin Moses, CEO and Chairman of Ablynx, will host a conference call webcast during which the half year results for 2010 will be presented, followed by a Q&A session. This event will be held on Thursday, 26 August 2010 at 4.00 p.m. CET.

The conference call will be webcast live and can be accessed through the home page of the Ablynx website (www.ablynx.com). Shortly thereafter, a replay version of the webcast will be accessible on our website under Investor Relations > Newsroom > Events and Presentations: http://www.ablynx.com/investorrelations/english/newsroom_eventsandpresentations.php



- ends -

About Ablynx [Euronext Brussels: ABLX] - http://www.ablynx.com

Founded in 2001 in Ghent, Belgium, Ablynx is a biopharmaceutical company focused on the discovery and development of Nanobodies, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases. The Company currently has over 240 employees. Ablynx completed a successful IPO on Euronext Brussels [ABLX] on 7 November 2007 and raised EUR50 million through an SPO in March 2010.

Ablynx is developing a portfolio of Nanobody-based therapeutics in a number of major disease areas, including inflammation, thrombosis, oncology and Alzheimer's disease. Ablynx now has over 25 programmes in its therapeutic pipeline including four Nanobodies in clinical development. So far, Nanobodies have been successfully generated against more than 220 different protein targets including several complex targets such as chemokines, GPCRs, ion channels and viruses, which are typically very difficult to address with conventional monoclonal antibodies. Efficacy data have been obtained in 35 in vivo models for Nanobodies against a range of different targets.

Ablynx has an extensive patent position in the field of Nanobodies for healthcare applications. It has exclusive and worldwide rights to more than 130 families of granted patents and pending patent applications, including the Hamers patents covering the basic structure, composition, preparation and uses of Nanobodies.

[HUG#1439039]

Complete version of the press release: http://hugin.info/137912/R/1439039/383468.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

All reproduction for further distribution is prohibited.

Source: Ablynx via Thomson Reuters ONE

Contact Information

  • For more information, please contact Ablynx:

    Dr. Edwin Moses
    Chairman and CEO
    t: +32 (0)9 262 00 07
    m: +44 (0)7771 954 193 / +32 (0)473 39 50 68
    e: Email Contact

    Eva-Lotta Allan
    Chief Business Officer
    t: +32 (0)9 262 00 75
    m: +32 (0)475 78 36 21 / +44 (0)7990 570 900
    e: Email Contact


    Wim Ottevaere
    Chief Financial Officer
    t: +32 (0)9 262 00 08
    e: Email Contact